Literature DB >> 22945792

A probable clinically significant interaction between warfarin and cloxacillin: three case reports.

Hossein Khalili1, Naemeh Nikvarz, Farhad Najmeddin, Simin Dashti-Khavidaki.   

Abstract

CASES: Three patients were admitted to the Imam Hospital, Tehran, Iran with a diagnosis of bacterial endocarditis. The patients had indications for valve replacement surgery and anticoagulant therapy. The administration of cloxacillin reduced the effect of warfarin, and subsequent increases in warfarin doses were unable to overcome this effect.
CONCLUSION: A decrease in warfarin anticoagulation effects was detected in our three patients following cloxacillin therapy for infective endocarditis. Penicillinase-resistant penicillins remain essential antibiotics in the treatment of severe infections caused by Staphylococcus aureus due to their bactericidal activity, safety, and cost. Thus, in situations where anticoagulants are indicated in patients with infective endocarditis, it would be better to replace warfarin with low-molecular-weight or unfractionated heparin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22945792     DOI: 10.1007/s00228-012-1384-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Interaction of dicloxacillin with warfarin.

Authors:  Christopher S Lacey
Journal:  Ann Pharmacother       Date:  2004-03-30       Impact factor: 3.154

2.  Proposal for a new tool to evaluate drug interaction cases.

Authors:  John R Horn; Philip D Hansten; Lingtak-Neander Chan
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

3.  Decreased INR response secondary to warfarin-flucloxacillin interaction.

Authors:  Alka Garg; Mushtaq Mohammed
Journal:  Ann Pharmacother       Date:  2009-07-07       Impact factor: 3.154

4.  High-dose intravenous flucloxacillin may affect warfarin therapy.

Authors:  Philip Y-I Choi; Katherine L Phillips; Ian Rae
Journal:  Med J Aust       Date:  2011-06-06       Impact factor: 7.738

5.  Warfarin-flucloxacillin interaction presenting as cardioembolic ischemic stroke.

Authors:  Aine Merwick; Niamh Hannon; Peter J Kelly; Killian O'Rourke
Journal:  Eur J Clin Pharmacol       Date:  2010-03-05       Impact factor: 2.953

6.  Prosthetic heart valve thrombosis during dicloxacillin therapy.

Authors:  S Halvorsen; T Husebye; H Arnesen
Journal:  Scand Cardiovasc J       Date:  1999       Impact factor: 1.589

Review 7.  Plasma protein binding displacement interactions--why are they still regarded as clinically important?

Authors:  P E Rolan
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

Review 8.  Continuation of warfarin-nafcillin interaction during dicloxacillin therapy.

Authors:  A T Taylor; D C Pritchard; A O Goldstein; J L Fletcher
Journal:  J Fam Pract       Date:  1994-08       Impact factor: 0.493

Review 9.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

10.  Enhanced anticoagulant effect of warfarin in a patient treated with cloxacillin.

Authors:  Srecko Marusic; Nives Gojo-Tomic; Vesna Bacic-Vrca; Miljenko Franic
Journal:  Int J Clin Pharmacol Ther       Date:  2012-06       Impact factor: 1.366

View more
  3 in total

Review 1.  Drug Interactions Affecting Oral Anticoagulant Use.

Authors:  Philip L Mar; Rakesh Gopinathannair; Brooke E Gengler; Mina K Chung; Arturo Perez; Jonathan Dukes; Michael D Ezekowitz; Dhanunjaya Lakkireddy; Gregory Y H Lip; Mike Miletello; Peter A Noseworthy; James Reiffel; James E Tisdale; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2022-05-27

2.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Authors:  Tore Bjerregaard Stage; Magnus Graff; Susan Wong; Louise Ladebo Rasmussen; Flemming Nielsen; Anton Pottegård; Kim Brøsen; Deanna L Kroetz; S Cyrus Khojasteh; Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

3.  Two Strategies for the Dosage of Acenocoumarol Co-Administered with Rifampicin in Staphylococcal Prosthetic Valve Endocarditis.

Authors:  Marcin Wełnicki; Małgorzata Buksińska-Lisik; Artur Mamcarz
Journal:  Antibiotics (Basel)       Date:  2021-01-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.